Skip to ContentSkip to Navigation
Research Medical oncology
University Medical Center Groningen

PI: An Reyners, MD PhD

A. Reyners

Position: MD
Contact: email
Phone number: +31 (0)50 361  1543
Publications: Pubmed


An Reyners is a medical oncologist specialized in gynaecological malignancies, gastrointestinal stromal tumors and palliative care at the department of Medical Oncology of the UMCG. She studied medicine at the University of Groningen, and obtained her PhD degree in 2003 at the UMCG. Additionally, she obtained an MSc in Palliative Medicine at Cardiff University, UK in 2009. She is chairperson of the Center of Expertise in Palliative Care at the UMCG and of the Consortium 'Ligare', a collaboration of all palliative care providers in the Northeast of the Netherlands working together to improve palliative care in the region withinin the framework of the Dutch National Program Palliative Care.

Her research focuses on palliative medicine, improving psychological care for breast cancer patients, reducing pain in patients undergoing palliative radiotherapy, and the effects of implementation of advance care planning. Moreover, she is the PI of several clinical studies in gynaecological and soft tissue malignancies. An’s research projects are funded by the Dutch Cancer Society, Pink Ribbon and ZonMW.

Group Members

  • P. Westerhof, radiotherapist in training, research within theme 'painful bone metastases and pain flare'
  • J. Geerling, nurse practitioner palliative care, research within theme 'pain education for patients with painful bone metastases'
  • J. Admiraal, psychologist, PhD trajectory regarding improvement of psychosocial care for breast cancer patients
  • I. IJpma, PhD trajectory within in Top Institute Food and Nutrition project 'sensory and liking'
  • J. Dalenberg, PhD trajectory within Top Institute Food and Nutrition project 'sensory and liking'
  • E. Broekman, internist in training, PhD trajectory regarding ovarian cancer treatment optimization
  • M. Kok, PhD trajectory regarding advance care planning for patients with advanced malignancies


  • Dr. Y.M. van der Linden, radiation oncologist, Radiation Institute Friesland.
  • Dr. A. de Graeff, medical oncologist, University Medical Center Utrecht.
  • Dr. D. Benoit, intensive care physician and hematologist, University Medical Center Gent (Appropricus study).
  • Top Institute Food and Nutrition Theme Sensory and Liking (University of Wageningen, Danone, FrieslandCampina and University Medical Center Groningen).

Projects in which An Reyners is involved

  • Efficiency research UMCG 2010: Neo-adjuvant chemotherapy, cytoreductive surgery with hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis of colorectal origin (NACHO-trial). Co-investigator.
  • KWF-CKS 2010: Pain education for patients with painful bone metastases undergoing palliatieve radiotherapy: reducing pain by increasing patient’s knowledge and self-management. Project leader.
  • Pink Ribbon WO 43: Individuele gedragsveranderende interventie ter bevordering van lichaamsbeweging tijdens en na borstkankerbehandeling. Project leader.
  • Dutch Pink Ribbon Foundation 08065. Improve psychosocial care for breast cancer patients.
  • ZonMW grant 115110007. Pain education for patients with painful bone metastases undergoing palliative radiotherapy: reducing pain by increasing patient’s knowledge and self-management.
  • ZonMW 11510009. Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: a multicenter double-blind placebo-controlled randomized study.
  • Alpe d'HuZes/KWF grant RUG 2013-6355: Treatment of gastrointestinal stromal tumors based on serial mutation analysis of circulating tumor DNA: GALLOP. Project Leader.
  • KWF RUG 2015-7235: Towards biomarker-driven combination immunotherapy in advanced stage serous ovarian cancer. Co-investigator.

Selected Publications

  • Bouma G, Admiraal JM, de Vries EG, Schröder CP, Walenkamp AM, Reyners AK. Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: A literature analysis. Crit Rev Oncol Hematol. 2015 Jan 31 [Epub ahead of print]
  • IJpma I, Renken RJ, ter Horst GJ, Reyners AK. Metallic taste in cancer patients with chemotherapy. Cancer Treat Rev. 41:179-86, 2015.
  • van Kruchten M, de Vries EF, Arts HJ, Jager NM, Bongaerts AH, Glaudemans AW, Hollema H, de Vries EG, Hospers GA, Reyners AK. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT. J Nucl Med. 56:50-5, 2015.
  • Piers RD, Azoulay E, Ricou B, DeKeyser Ganz F, Max A, Michalsen A, Azevedo Maia P, Owczuk R, Rubulotta F, Meert AP, Reyners AK, Decryenaere J, Benoit DD, Appropricus Study Group if the Ethics Section of the European Society of Intensive Care Medicine. Inappropriate care in European ICUs: confronting views from nurses and junior and senior physicians. Chest. 146:267-75, 2014.
  • Westhoff PG, de Graeff A, Reyners AK, Monninkhof EM, Rodenhuis CC, van Vulpen M, Leer JW, Marijnen CA, van der Linden YM; Dutch Bone Metastasis Study Group. Effect of age on response to palliative radiotherapy and quality of life in patients with painful bone metastases. Radiother Oncol. 111:264-9, 2014.
  • van Kruchten M, Hospers GA, Glaudemans AW, Hollema H, Arts HJ, Reyners AK. Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case-report and review of the literature. Eur J Cancer. 49:3850-5, 2013.
  • van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res. 18:6306-14, 2012.
  • Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 92:503-10, 2012.
  • Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, Friberg LE, Schiavon G, Wiemer EA, Verweij J, Loos WJ, Mathijssen RH, de Giorgi U. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 18:5780-7, 2012.
  • Reyners AK , de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M, Willemse PH; the DoCaCel Study Group.A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Annals Oncol. 23:2896-902, 2012.
  • den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, de Vries EG. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett. 332:194-201, 2013.
  • van der Bilt AR, de Vries EG, de Jong S, Timmer-Bosscha H, van der Zee AG, Reyners AK. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Crit Rev Oncol Hematol. 84:224-42, 2012.
  • Altena R, Gietema JA, van Veldhuisen DJ, Reyners AK. Pregnancy unbosoms the heart of breast cancer survivors. Ann Oncol. 23:2206-8, 2012.
  • Piers RD, Azoulay E, Ricou B, Dekeyser Ganz F, Decruyenaere J, Max A, Michalsen A, Maia PA, Owczuk R, Rubulotta F, Depuydt P, Meert AP, Reyners AK, Aquilina A, Bekaert M, Van den Noortgate NJ, Schrauwen WJ, Benoit DD; APPROPRICUS Study Group of the Ethics Section of the ESICM. Perceptions of appropriateness of care among European and Israeli intensive care unit nurses and physicians. JAMA. 306:2694-703, 2011.
  • Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, Molmans BH, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int J Cancer. 131:E670-80, 2012.
  • Meeuse JJ, van der Linden YM, Post WJ, Wanders R, Gans RO, Leer JW, Reyners AK. Cancer patients use hospital-based care until death: a further analysis of the Dutch Bone Metastasis Study. J Palliat Med. 14:1117-27, 2011.
  • Jansman FG, Reyners AK, van Roon EN, Smorenburg CH, Helgason HH, le Comte M, Wensveen BM, van den Tweel AM, de Blois M, Kwee W, Kerremans AL, Brouwers JR; Scientific Institute for Dutch Pharmacists (WINAp); Dutch Society for Medical Oncology (NVMO); Dutch Society of Clinical Pharmacology and Biopharmacy (NVKF&B). Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther. 33:305-14, 2011.
  • Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Metformin: taking away the candy for cancer? Eur J Cancer. 46: 2369-80, 2010.
  • van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AKL, Mathijssen RHJ, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JAM, Guchelaar HJ, Gelderblom H. Pharmacogenetic Pathway Analysis for determination of Sunitinib-induced Toxicity. J Clin Oncol. 27: 4406-12, 2009.
Last modified:21 August 2015 10.23 a.m.